Patents

Helsinn v. Teva: A Secret Sale Still Counts Under the America Invents Act

The Supreme Court held that a confidential commercial sale to a third party can place an invention 'on sale' under the AIA, just as it did under the prior statute.

May 19, 2025
Pharmaceutical vials on a laboratory production line
Helsinn announced its palonosetron distribution deal years before filing, but kept the specific dose confidential. Shutterstock
Educational content, not legal advice. This article explains general legal concepts. It does not create an attorney–client relationship. For your specific situation, consult a licensed attorney.

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123, No. 17-1229 (U.S. Jan. 22, 2019), resolved the most-watched novelty question of the post-AIA era: whether the America Invents Act’s rewording of the on-sale bar had quietly carved out secret or confidential sales. Argued December 4, 2018, and decided January 22, 2019, the case produced a short, unanimous opinion by Justice Thomas. The answer was no. A commercial sale to a third party who is contractually bound to keep the invention confidential can still place that invention “on sale” under 35 U.S.C. § 102(a)(1). Congress, the Court held, had reenacted a settled term of art and is presumed to have carried its established meaning forward.

At a glance

  • Case: Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 123, No. 17-1229 (U.S. Jan. 22, 2019)
  • Author: Justice Thomas, for a unanimous Court
  • Below: Federal Circuit held the claims invalid; the Supreme Court affirmed
  • Patent: U.S. Patent No. 8,598,219, directed to a fixed 0.25 mg dose of palonosetron (marketed as Aloxi) for chemotherapy-induced nausea and vomiting — a post-AIA patent
  • Statute: AIA on-sale bar, 35 U.S.C. § 102(a)(1)
  • Holding: A sale to a third party obligated to keep the invention confidential can trigger the on-sale bar; the AIA did not change the established meaning of “on sale”
  • Disposition: Affirmed; claims invalid

The facts: a public deal with a private dose

Helsinn developed palonosetron, a treatment for chemotherapy-induced nausea and vomiting. Nearly two years before it filed the patent application at issue, Helsinn entered into two agreements in April 2001 with MGI Pharma, a Minnesota company: a license agreement and a supply-and-purchase agreement. Together they gave MGI the right to distribute, promote, market, and sell the 0.25 mg and 0.75 mg doses of palonosetron in the United States, in exchange for an up-front payment and future royalties.

The transaction itself was no secret. Helsinn and MGI announced the agreements in a joint press release and MGI reported them in filings with the Securities and Exchange Commission. What the public did not learn was the specific invention later claimed — the 0.25 mg dose. The agreements required MGI to keep confidential any proprietary information, including the dosage details, that it received under the deal. Helsinn filed the provisional application that anchored its patent family in January 2003, more than a year after the 2001 agreements, and the ‘219 patent claimed the AIA’s effective date because it issued from a later application subject to the new statute.

When Helsinn sued Teva for filing an abbreviated new drug application to market a generic palonosetron, Teva responded that the ‘219 patent was invalid: the 0.25 mg dose had been “on sale” more than a year before the critical date, by virtue of the MGI agreements. The district court disagreed, reasoning that the AIA’s new language required a sale that made the invention available to the public. The Federal Circuit reversed, and the Supreme Court took the case to settle the statutory question.

The AIA argument: did “otherwise available to the public” rewrite “on sale”?

The pre-AIA statute barred a patent if the invention was “on sale” more than one year before the application. The AIA recast § 102 so that a patent is barred if the claimed invention was “patented, described in a printed publication, or in public use, on sale, or otherwise available to the public” before the effective filing date. Helsinn’s argument rested entirely on the new trailing phrase. Reading “on sale” in the light of “otherwise available to the public,” Helsinn contended that Congress had limited the bar to sales that actually disclosed the invention to the public. A confidential sale to MGI, which revealed the deal but not the dose, would then fall outside the reframed bar.

The Court rejected the reading. Justice Thomas emphasized that “on sale” was a term with a long and settled judicial construction. Before the AIA, the Federal Circuit had squarely held that even a secret sale — one that does not disclose the invention to the public — could trigger the bar. When Congress reenacted the phrase “on sale” without elaboration, it is presumed to have adopted that earlier interpretation. The catch-all “or otherwise available to the public,” the Court reasoned, was a broadening residual clause that captured additional, previously uncovered disclosures; it was not a limiting gloss that silently narrowed the discrete, enumerated category of “on sale” that precedes it. Reading the catch-all to constrict “on sale” would, in the Court’s view, attribute to a generic catch-all phrase the power to upend a substantial body of established law — a result Congress would have signaled far more clearly.

The Court was careful about what it was deciding. It did not hold that any sale, however informal or secret, qualifies, nor did it parse what makes a transaction a “sale” rather than something else. It held only that the existence of a confidentiality obligation does not, by itself, take a commercial sale outside the bar. Because the MGI agreements were commercial sales of the claimed invention more than a year before filing, the ‘219 claims were invalid.

Reading the statute against its history

The opinion is a study in how the Court treats statutory reenactment. Two interpretive presumptions did the work. First, the presumption that Congress legislates against the backdrop of existing judicial constructions: a settled term of art carries its accumulated meaning forward unless Congress clearly displaces it. Second, the principle that catch-all language at the end of a list ordinarily supplements rather than redefines the specific items that precede it. Helsinn’s reading would have inverted both presumptions, allowing a residual clause to rewrite a precise term with decades of precedent behind it.

The decision also reflects the policy logic of the on-sale bar. The bar discourages an inventor from commercially exploiting an invention for an extended period before seeking a patent, thereby effectively extending the monopoly. A confidential sale is, if anything, the paradigmatic case the bar targets — the inventor profits while keeping the public in the dark. Treating secrecy as a safe harbor would have rewarded precisely the behavior the doctrine exists to deter.

Open questions

The opinion deliberately left edges unresolved. It did not define the universe of transactions that count as “sales,” so disputes persist over licenses, supply agreements, manufacturing arrangements, and transfers that may not be commercial sales at all. The Court also declined to address whether the AIA changed the rule for “public use,” leaving open whether a secret or confidential use is treated the same way as a secret sale. And because Helsinn involved a sale of the claimed product itself, it did not resolve how the bar applies to sales of a product made by a later-claimed secret process — a question the Federal Circuit took up in Celanese v. ITC (2024), reading Helsinn to preserve the pre-AIA process-patent forfeiture rule.

Implications

  • Confidentiality is not a shield. A nondisclosure obligation around a commercial sale does not stop the on-sale clock. Build patent timing around the date of any commercial agreement, not around whether it is public.
  • Watch supply and license deals. Distribution, supply, and license agreements that commit a partner to buy or sell the claimed invention can be invalidating sales, even when the public sees only the announcement.
  • File before commercialization, not after the press release. The relevant trigger is the commercial transaction. Public secrecy about the technical details will not buy extra time.
  • The AIA preserved, not relaxed, the bar. Practitioners should not treat “otherwise available to the public” as a liberalizing safe harbor for confidential dealings.
  • Diligence must reach private agreements. Validity and freedom-to-operate analyses should examine confidential pre-filing sales and supply contracts, not just public disclosures.

Frequently asked questions

Did the sale have to disclose the invention to the public? No. That is the heart of the holding. The MGI agreements were publicly announced, but the specific 0.25 mg dose was kept confidential. The Court held that the bar applied anyway: a sale need not make the invention available to the public to count as “on sale.”

Does this mean every license or agreement is a “sale”? No. The Court did not decide what range of transactions qualifies as sales. It held only that confidentiality does not remove a commercial sale from the bar. Whether a particular license or supply arrangement is itself a “sale” remains a fact-specific question.

How does Helsinn relate to Pfaff? Pfaff v. Wells Electronics (1998) set the two-part framework — a commercial offer plus “ready for patenting.” Helsinn addressed a different question: whether the AIA’s new text changed which sales count. It held that the established meaning of “on sale,” including secret sales, survived the statutory rewrite.

Authorities and sources